Search Results - "Crux, Richard"

Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA) by Gordon, Anderley, Challoner, Benjamin, Athauda, Avani, Woolston, Andrew, Mansukhani, Sonia, Dunstan, Matt, Petrou, Nikoletta, Khabra, Komel, Lazaro-Alcausi, Retchel, Crux, Richard, Borja, Victoria, Begum, Ruwaida, Rana, Isma, Rao, Sheela, Kumar, Sacheen, Cunningham, David, Chau, Ian, Starling, Naureen, Chaudry, M. Asif, Gerlinger, Marco

“…446 Background: ICONIC evaluated 4+4 cycles of FLOT-A (2-weekly standard FLOT with 10mg/kg of the anti-PDL1 antibody avelumab) for perioperative treatment of…”
Get full text

Genetic and immune landscape evolution in MMR-deficient colorectal cancer by Challoner, Benjamin R, Woolston, Andrew, Lau, David, Buzzetti, Marta, Fong, Caroline, Barber, Louise J, Anandappa, Gayathri, Crux, Richard, Assiotis, Ioannis, Fenwick, Kerry, Begum, Ruwaida, Begum, Dipa, Lund, Tom, Sivamanoharan, Nanna, Sansano, Harold B, Domingo-Arada, Melissa, Tran, Amina, Pandha, Hardev, Church, David, Eccles, Bryony, Ellis, Richard, Falk, Stephen, Hill, Mark, Krell, Daniel, Murugaesu, Nirupa, Nolan, Luke, Potter, Vanessa, Saunders, Mark, Shiu, Kai-Keen, Guettler, Sebastian, Alexander, James L, Lázare-Iglesias, Héctor, Kinross, James, Murphy, Jamie, von Loga, Katharina, Cunningham, David, Chau, Ian, Starling, Naureen, Ruiz-Bañobre, Juan, Dhillon, Tony, Gerlinger, Marco

“…Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune…”
Get full text

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study by Lau, David, Kalaitzaki, Eleftheria, Church, David N, Pandha, Hardev, Tomlinson, Ian, Annels, Nicola, Gerlinger, Marco, Sclafani, Francesco, Smith, Gillian, Begum, Ruwaida, Crux, Richard, Gillbanks, Angela, Wordsworth, Sarah, Chau, Ian, Starling, Naureen, Cunningham, David, Dhillon, Tony

“…Background10%–15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease…”
Get full text

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study by Lau, David, Cunningham, David, Gillbanks, Angela, Crux, Richard, Powell, Rachel, Kalaitzaki, Eleftheria, Annels, Nicola E., Sclafani, Francesco, Gerlinger, Marco, Chau, Ian, Tomlinson, Ian, Starling, Naureen, Pandha, Hardev S., Church, David N., Dhillon, Tony

“…Abstract only TPS3615 Background: Colon cancer with deficient mismatch repair (dMMR) and POLE mutations are characterised by a high tumor mutational burden…”
Get full text

Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer by Challoner, Benjamin R., Woolston, Andrew, Lau, David, Buzzetti, Marta, Barber, Louise J., Lund, Tom, Sansano, Harold B., von Loga, Katharina, Lázare-Iglesias, Héctor, Begum, Ruwaida, Crux, Richard, Cunningham, David, Chau, Ian, Starling, Naureen, Ruiz-Bañobre, Juan, Dhillon, Tony, Gerlinger, Marco

“…This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Proffered Abstracts section (PR012) of the…”
Get full text

Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer by Challoner, Benjamin R., Woolston, Andrew, Lau, David, Buzzetti, Marta, Barber, Louise J., Lund, Tom, Sansano, Harold B., von Loga, Katharina, Lázare-Iglesias, Héctor, Begum, Ruwaida, Crux, Richard, Cunningham, David, Chau, Ian, Starling, Naureen, Ruiz-Bañobre, Juan, Dhillon, Tony, Gerlinger, Marco

“…Mismatch repair deficient (MMRd) CRCs have high mutation/neo-antigen loads, leading to high immunogenicity and good immunotherapy response rates. We reasoned…”
Get full text

Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma by Gerlinger, Marco, Gordon, Anderley, Barber, Louise J., Laliotis, Georgios, Athauda, Avani, Challoner, Benjamin, Woolston, Andrew, Mansukhani, Sonia, Dunstan, Matt, Petrou, Nikoletta, Khabra, Komel, Lazaro-Alcausi, Retchel, Crux, Richard, Borja, Victoria, Begum, Ruwaida, Rana, Isma, Palsuledesai, Charuta, Malhotra, Meenakshi, Liu, Minetta, Jurdi, Adham, Sharma, Shruti, Rao, Sheela, Kumar, Sacheen, Cunningham, David, Chau, Ian, Starling, Naureen, Chaudry, M Asif

“…Background: The utility of molecular residual disease (MRD) detection by circulating tumor (ct)DNA in early-stage (pT2+ or N+, M0) esophagogastric…”
Get full text